Other pharmacological mechanisms

Other pharmacological mechanisms is a residual category in the pharmacological dimension that holds psychoactive substances whose primary mechanism does not map cleanly onto any better-characterised receptor class — opioid, GABAergic, monoaminergic, glutamatergic, cannabinoid, or the other major groupings. Membership is defined by exclusion from those containers rather than by a shared positive target.

There is no shared mechanism across this class. The grouping is defined by exclusion, so members do not converge on a common molecular target, signal-transduction cascade, or physiological endpoint. The pharmacology is read one member at a time.

What the members share at the pharmacological level is therefore methodological rather than mechanistic: each falls outside the standard receptor-class containers, and for myristicin and benzydamine the literature itself is openly uncertain about the central substrate. Clonidine sits at the opposite pole — its mechanism is well-defined, but the receptor systems it engages (imidazoline in particular) are uncommon enough that no broader class accommodates it.

The class currently has three named members, each illustrating a different reason for placement in a residual category.

These three differ in chemistry, clinical status, accessibility, and the kind of effects they produce. What they share is exclusion from the better-defined pharmacological classes, not any feature of the experience or the underlying biology.

There is no unified class-wide effect profile. Because the members act through unrelated mechanisms, their subjective and clinical trajectories diverge and should not be read as one phenomenon.

The qualitative thread, weak as it is, is that each member can compromise cognition, consciousness, or cardiovascular control in clinically significant ways — through delirium, psychosis, or sedation and hypotension respectively — but the routes to those endpoints are entirely different, and risk on any given member must be read from that member's page, not generalised across the class.

For myristicin, the documented risk is an anticholinergic and sympathomimetic mixed toxidrome — tachycardia, agitation, hallucinations, and in rare cases delirium requiring emergency management. A forensic fatality has been reported in which myristicin was identified in postmortem serum alongside another CNS depressant, indicating that co-ingestion sharply raises risk.^[7]

The substance's accessibility as a culinary spice lowers the barrier to inadvertent overdose, and the delayed onset (effects may take two or more hours to develop) raises the risk of repeat ingestion before the initial dose is felt.

For benzydamine, the central risk is psychiatric. A systematic review documents recurrent presentations of psychosis, paranoia, and agitation with high-dose oral use, and a published case describes persistent chronic psychosis following repeated misuse.^[1][8] Reinforcing properties demonstrated in preclinical cross-sensitisation models suggest meaningful abuse liability.^[1] Seizures have also been reported at high doses, and OTC availability in many jurisdictions means access is not medically gated.

For clonidine, the defining acute risk is cardiovascular: supratherapeutic doses can produce severe hypotension and bradycardia.^[6]

On interaction themes, the literature is sparse but coherent. Myristicin's weak MAO-inhibiting activity creates a theoretical interaction with serotonergic and sympathomimetic agents. Both myristicin and benzydamine carry anticholinergic components that could be expected to add to the burden of other anticholinergic drugs, though this has not been systematically studied. Clonidine's hypotensive and bradycardic effects are potentiated by other agents that lower blood pressure or heart rate.

Tolerance & dependence

Tolerance and dependence patterns are entirely member-specific, and there is no pharmacological basis for cross-tolerance between any of the three.

Tolerance to myristicin has not been systematically characterised. The dysphoric character of most nutmeg experiences appears to limit habitual use, and no dependence syndrome has been described in the clinical literature.

A formal physical dependence syndrome has not been established for benzydamine either, but reinforcing properties in preclinical models and the chronic-psychosis case literature indicate that repeated high-dose use may produce lasting neurobiological changes.^[1][8] Recovery from benzydamine-associated psychosis may be prolonged and can require antipsychotic treatment.

Clonidine produces physical dependence through adrenergic adaptation. With continued use, postsynaptic alpha-2 receptors downregulate, setting up a rebound state.

This class sits at the root of the pharmacological dimension — it has no parent and no sibling classes. Its position in the taxonomy is therefore best understood by what it is NOT (the major receptor classes: opioid, GABAergic, monoaminergic, glutamatergic, cannabinoid, and so on) and by the more specific child categories that sit beneath it.

The child classes — antioxidant, methyl donor, mood stabilizer, nitric oxide donor, phosphocreatine system substrate, TRPV1 agonist, and vasodilator — each represent a more specific mechanism that can accommodate substances as their pharmacology becomes clearly characterised.

Of the current members, myristicin's TRPV1 agonism makes it a candidate for the TRPV1-agonist child class in addition to its placement here,^[3] and clonidine's peripheral vasodilatory effects, secondary to its central sympatholysis, touch the vasodilator category.

The functional takeaway for readers is that this parent class is a holding category, not a coherent pharmacological grouping. A substance landing here signals that it does not fit the standard receptor classes — either because its mechanism is genuinely outlying (clonidine), or because its central pharmacology has not been adequately studied (benzydamine, myristicin). The substance's own page is the right place to read its mechanism, effects, and risks; this class page only frames the gap that placed it here.